An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

• Status: Approved for marketing
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Biotech, Inc.
• Collaborator: Pharmacyclics LLC.

Criteria

Inclusion Criteria:

• Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.

Exclusion Criteria:

• Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.

• Patients previously treated with ibrutinib are not eligible.

• Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.